Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Breast. 2020 Feb;49:63-69. doi: 10.1016/j.breast.2019.10.017. Epub 2019 Nov 6.
We conducted this study to investigate the prognosis and failure pattern after breast-conserving treatment (BCT) in patients with occult breast cancer (OBC) with negative breast magnetic resonance imaging (MRI) (MRI-OBC).
Survival rates and failure patterns in 66 patients who received axillary lymph node dissection (ALND) and BCT for MRI-OBC between 2001 and 2013 at seven hospitals were analyzed. OBC was defined as adenocarcinoma in the axillary lymph node (ALN) +/- supraclavicular (SCN) or internal mammary lymph node (IMN) with a negative breast MRI.
Fifty-four patients had only ALN metastasis (ALN only), and 12 patients had ALN metastasis along with SCN or IMN metastasis (ALN + SCN/IMN). Median follow-up was 82 months. The 5-year overall, disease-free, and breast cancer-free survival rates were 93.4%, 92.1%, and 96.8%, respectively. Nine patients experienced recurrence: breast (n = 4), regional lymph nodes (RLN, n = 1), distant metastases (DM, n = 2), breast/RLN (n = 1), and breast/RLN/DM (n = 1). Five-year disease-free survival was significantly higher in ALN only patients compared to ALN + SCN/IMN patients (96.1% vs. 75.0%; p = 0.02).
Patients with MRI-OBC were successfully treated with BCT. There was a small risk of ipsilateral breast cancer recurrence. Failure patterns depended on the extent of initial disease.
本研究旨在探讨阴性乳腺磁共振成像(MRI)(MRI-OBC)患者接受保乳治疗(BCT)后的预后和失败模式。
分析了 2001 年至 2013 年期间在七家医院接受腋窝淋巴结清扫术(ALND)和 BCT 治疗的 66 例 MRI-OBC 患者的生存率和失败模式。OBC 定义为腋窝淋巴结(ALN)+/-锁骨上(SCN)或内乳淋巴结(IMN)的腺癌,伴阴性乳腺 MRI。
54 例患者仅存在 ALN 转移(仅 ALN),12 例患者存在 ALN 转移合并 SCN 或 IMN 转移(ALN+SCN/IMN)。中位随访时间为 82 个月。5 年总生存率、无病生存率和乳腺癌无病生存率分别为 93.4%、92.1%和 96.8%。9 例患者复发:乳房(n=4)、区域淋巴结(RLN,n=1)、远处转移(DM,n=2)、乳房/RLN(n=1)和乳房/RLN/DM(n=1)。仅 ALN 患者的 5 年无病生存率明显高于 ALN+SCN/IMN 患者(96.1% vs. 75.0%;p=0.02)。
MRI-OBC 患者成功接受了 BCT 治疗。同侧乳腺癌复发的风险较小。失败模式取决于初始疾病的范围。